Jacobson Pharma Corporation Limited

SEHK:2633 株式レポート

時価総額:HK$1.2b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Jacobson Pharma 過去の業績

過去 基準チェック /36

Jacobson Pharmaの収益は年間平均-2.1%の割合で減少していますが、 Pharmaceuticals業界の収益は年間 増加しています。収益は年間5.9% 2.5%割合で 増加しています。 Jacobson Pharmaの自己資本利益率は12.6%であり、純利益率は12.8%です。

主要情報

-3.6%

収益成長率

-2.8%

EPS成長率

Pharmaceuticals 業界の成長5.6%
収益成長率2.7%
株主資本利益率8.8%
ネット・マージン12.7%
前回の決算情報31 Mar 2024

最近の業績更新

Jacobson Pharma's (HKG:2633) Profits May Not Reveal Underlying Issues

Dec 21
Jacobson Pharma's (HKG:2633) Profits May Not Reveal Underlying Issues

Recent updates

Increases to Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Might Cool off for now

Aug 21
Increases to Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Might Cool off for now

Jacobson Pharma's (HKG:2633) Profits May Not Reveal Underlying Issues

Dec 21
Jacobson Pharma's (HKG:2633) Profits May Not Reveal Underlying Issues

Jacobson Pharma's (HKG:2633) Dividend Is Being Reduced To HK$0.025

Nov 27
Jacobson Pharma's (HKG:2633) Dividend Is Being Reduced To HK$0.025

These 4 Measures Indicate That Jacobson Pharma (HKG:2633) Is Using Debt Reasonably Well

Jun 20
These 4 Measures Indicate That Jacobson Pharma (HKG:2633) Is Using Debt Reasonably Well

Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's

Nov 28
Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's

Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.0268

Sep 25
Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.0268

Should Shareholders Reconsider Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Package?

Sep 16
Should Shareholders Reconsider Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Package?

Jacobson Pharma's (HKG:2633) Shareholders Will Receive A Bigger Dividend Than Last Year

Jul 28
Jacobson Pharma's (HKG:2633) Shareholders Will Receive A Bigger Dividend Than Last Year

Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's

Jul 14
Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's

Does Jacobson Pharma (HKG:2633) Have A Healthy Balance Sheet?

Feb 09
Does Jacobson Pharma (HKG:2633) Have A Healthy Balance Sheet?

Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.012

Nov 29
Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.012

Jacobson Pharma (HKG:2633) Is Reducing Its Dividend To HK$0.015

Sep 24
Jacobson Pharma (HKG:2633) Is Reducing Its Dividend To HK$0.015

Here's Why It's Unlikely That Jacobson Pharma Corporation Limited's (HKG:2633) CEO Will See A Pay Rise This Year

Sep 16
Here's Why It's Unlikely That Jacobson Pharma Corporation Limited's (HKG:2633) CEO Will See A Pay Rise This Year

Kwing Tong Lam Is The Independent Non-Executive Director of Jacobson Pharma Corporation Limited (HKG:2633) And They Just Picked Up 28% More Shares

Feb 03
Kwing Tong Lam Is The Independent Non-Executive Director of Jacobson Pharma Corporation Limited (HKG:2633) And They Just Picked Up 28% More Shares

A Look At The Fair Value Of Jacobson Pharma Corporation Limited (HKG:2633)

Jan 24
A Look At The Fair Value Of Jacobson Pharma Corporation Limited (HKG:2633)

Here's Why Jacobson Pharma (HKG:2633) Has A Meaningful Debt Burden

Jan 11
Here's Why Jacobson Pharma (HKG:2633) Has A Meaningful Debt Burden

Does Jacobson Pharma's (HKG:2633) CEO Salary Compare Well With The Performance Of The Company?

Dec 27
Does Jacobson Pharma's (HKG:2633) CEO Salary Compare Well With The Performance Of The Company?

Is It Smart To Buy Jacobson Pharma Corporation Limited (HKG:2633) Before It Goes Ex-Dividend?

Dec 12
Is It Smart To Buy Jacobson Pharma Corporation Limited (HKG:2633) Before It Goes Ex-Dividend?

Reflecting on Jacobson Pharma's (HKG:2633) Share Price Returns Over The Last Three Years

Dec 03
Reflecting on Jacobson Pharma's (HKG:2633) Share Price Returns Over The Last Three Years

収支内訳

Jacobson Pharma の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

SEHK:2633 収益、費用、利益 ( )HKD Millions
日付収益収益G+A経費研究開発費
31 Mar 241,4681863320
31 Dec 231,8112214230
30 Sep 231,9192174580
30 Jun 231,8522344430
31 Mar 231,2681752980
31 Dec 221,4892073600
30 Sep 221,4272033470
30 Jun 221,5111903730
31 Mar 221,5961783980
31 Dec 211,5481663990
30 Sep 211,5011544000
30 Jun 211,4731644040
31 Mar 211,4461744080
31 Dec 201,4781834050
30 Sep 201,5101914030
30 Jun 201,5412034020
31 Mar 201,5712144010
30 Sep 191,4192733650
30 Jun 191,4492593530
31 Mar 191,4782453410
31 Dec 181,6632353430
30 Sep 181,6222193350
30 Jun 181,5852113370
31 Mar 181,5492023390
31 Dec 171,4862023210
30 Sep 171,4242033030
30 Jun 171,3401913040
31 Mar 171,2561793040
31 Dec 161,1881423160
30 Sep 161,1411423220
30 Jun 161,1121443070
31 Mar 161,0841462930
31 Dec 151,0431452750
31 Mar 159481022460
31 Mar 149261722660

質の高い収益: 2633は 高品質の収益 を持っています。

利益率の向上: 2633の現在の純利益率 (12.7%)は、昨年(14.1%)よりも低くなっています。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: 2633の収益は過去 5 年間で年間2.1%減少しました。

成長の加速: 2633の過去 1 年間の収益成長率 ( 6.4% ) は、5 年間の平均 ( 年間-3.6%を上回っています。

収益対業界: 2633の過去 1 年間の収益成長率 ( 6.4% ) はPharmaceuticals業界-5%を上回りました。


株主資本利益率

高いROE: 2633の 自己資本利益率 ( 12.6% ) は 低い とみなされます。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘